Company Overview and News

27
48 Of 104 S&P 500 'Safer' Dividend Stocks Yield 3% To 6.35% For August

2018-08-19 seekingalpha - 2
48 of 104 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive one-year returns, and free cash-flow yields greater than their dividend-yields 8/15/18.
HCN PM PFG MET STX OPRF PRU VZA PM IP AVGO WELL LEG MO VTR PRU INPAP PFK O PRH CVX VZ SPG BRCM PJH IVZ

116
Tracking Yacktman Asset Management Portfolio - Q2 2018 Update

2018-08-06 seekingalpha - 2
Yacktman Asset Management decreased Twenty-First Century Fox, Microsoft, Sysco, and Cisco Systems substantially during the quarter.
ATHTF SYY XOM ULVR AVP RDI CHRW UNLNF UHAL SYK CSCO CMCSK ABBV HSY MO CRMT FOX GLW BAC HSYFB NWS NWSA UNLYF INFY BRK.A JNJ BK INFY ABBV MSFT CLX FOXA WFCNP PG CCV CCZ BAC COP OTEL PM RDIB NWS KO ORCL DIS WFC GJV UL UN CMCSA ANTM PEP CCV.CL OCLCF ANTX

62
S&P 500 'Safer' Dividend Stocks Yield 4.2% To 6% For June

2018-06-08 seekingalpha
35 of 90 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive one-year returns, and free cash-flow yields greater than their dividend-yields 6/5/18.
REG PM PFG MET STX OPRF PRU VZA PM WELL LEG PAYX VTR PRU PFK O PEP PRH CVX VZ DLR SPG QCOM PJH IVZ

564
Tracking Yacktman Asset Management Portfolio - Q1 2018 Update

2018-05-10 seekingalpha - 3
This article is part of a series that provides an ongoing analysis of the changes made to Yacktman's 13F stock portfolio on a quarterly basis. It is based on Yacktman Asset Management's regulatory 13F Form filed on 05/09/2018. Please visit our Tracking Yacktman Asset Management series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
ATHTF SYY XOM ULVR AVP RDI CHRW UNLNF HPE UHAL VIAB SYK CSCO CMCSK ABBV MMM CRMT MO FOX STT GLW NWS NWSA UNLYF INFY CTSH BRK.A JNJ BK MSFT ABBV CLX FOXA ESRX WFCNP PM MTSI PG CCV CCZ USB COP BAC GS OTEL RDIB PM NWS KO ORCL DIS WFC GJV UL UN CMCSA ANTM PEP CCV.CL OCLCF HPQ ANTX

60
S&P 500 'Safer' Dividend Stock Yield Leaders Are Welltower, Ventas, & Ford For May

2018-05-06 seekingalpha
46 of 114 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive one-year returns, and free cash-flow yields greater than their dividend-yields 5/3/18.
PM PFG MET STX OPRF PRU ETN VZA PM IP WELL LEG VTR PRU INPAP PFK O PEP PRH VZ SPG QCOM PJH IVZ

27
40 Largest Companies Reporting Earnings Next Week | Bespoke Investment Group

2018-04-13 bespokepremium
Below is a snapshot of the 40 largest companies set to report earnings next week. For each stock, we show its current consensus EPS and revenue estimate, and we also show each stock’s historical EPS and revenue beat rate. (Additional earnings season info is available with a Bespoke Premium free trial.)
GEC GE PM PPG GNE MS

46
S&P 500 'Safer' Dividend Gains Led By General Motors, Qualcomm, And Invesco For March

2018-03-16 seekingalpha
19 of 81 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive one-year returns, and free cash-flow yields greater than their dividend-yields 3/13/18.
PM MET STX PM KSS SPG GM HST QCOM FE PFE IVZ

46
S&P 500 'Safer' Dividend Gains Led By General Motors, Qualcom, & Invesco For March

2018-03-16 seekingalpha
19 of 81 S&P 500 Index top-yield dividend stocks were labeled as "safer" for dividends because they showed positive one-year returns, and free cash-flow yields greater than their dividend-yields 3/13/18.
PM MET STX PM KSS SPG GM HST QCOM FE PFE IVZ

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:PM / PHILIP MORRIS INTL on message board site Silicon Investor.

Wennerstrom Semi Equipment Analysis Wennerstrom Semi Equipment Analysis Wennerstrom Semi Equipment Analysis Free Float Trading/ Portfolio Development/ Index Stategies Free Float Trading/ Portfolio Development/ Index Stategies Free Float Trading/ Portfolio Development/ Index Stategies
J.P. Morgan Chase (JPM) J.P. Morgan Chase (JPM) J.P. Morgan Chase (JPM) RPM, Inc. (RPOW) RPM, Inc. (RPOW) RPM, Inc. (RPOW)
PMX.V - ProAm Exploration Corp PMX.V - ProAm Exploration Corp PMX.V - ProAm Exploration Corp WrapMail WrapMail WrapMail
PMC-Sierra (PMCS) PMC-Sierra (PMCS) PMC-Sierra (PMCS) EWPMF East West Petroleum EWPMF East West Petroleum EWPMF East West Petroleum
EWPMF East West Petroleum EWPMF East West Petroleum EWPMF East West Petroleum ChipMOS ChipMOS ChipMOS